Relay Therapeutics, Inc. — Director's Dealing 2021

Nov 17, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Relay Therapeutics, Inc. (RLAY)
CIK: 0001812364
Period of Report: 2021-11-15

Reporting Person: Adams Brian (General Counsel)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-11-15	Common Stock	M	6500	$4.12	Acquired	31784	Direct
2021-11-15	Common Stock	S	6500	$35.42	Disposed	25284	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-11-15	Stock Option (Right to Buy)	$4.12	M	6500	Disposed	2028-03-22	Common Stock (6500)	Direct

Footnotes

F1: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 28, 2020.

F2: Includes 13,887 shares underlying RSUs.

F3: This transaction was executed in multiple trades at prices ranging from $35.03 to $35.80. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

F4: Twenty-five percent (25%) of the shares underlying this option vested on March 19, 2019 and the remainder shall vest in equal quarterly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date.